Rubin Jonathan
Insider CIK 1836067 · SUPN Sr. VP, Chief Medical Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-10-30 | 2026-11-02 | 70,000 | — | $0 | 70,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-08-12 | 2026-08-14 | 750 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-08-12 | 2026-08-14 | 750 | — | $0 | 14,342 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-08-12 | 2026-08-14 | 363 | $46.57 | $16.9K | 13,979 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-08-12 | 2026-08-14 | 750 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-08-12 | 2026-08-14 | 363 | $46.57 | $16.9K | 13,979 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-08-12 | 2026-08-14 | 750 | — | $0 | 14,342 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-07-29 | 2026-07-31 | 750 | — | $0 | 750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-07-29 | 2026-07-31 | 750 | — | $0 | 750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-25 | 2026-02-26 | 1,250 | — | $0 | 1,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-25 | 2026-02-26 | 675 | $50.69 | $34.2K | 13,341 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-25 | 2026-02-26 | 1,250 | — | $0 | 14,016 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-24 | 2026-02-25 | 750 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-24 | 2026-02-25 | 1,250 | — | $0 | 2,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-24 | 2026-02-25 | 1,125 | — | $0 | 3,375 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-24 | 2026-02-25 | 1,250 | — | $0 | 13,437 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-24 | 2026-02-25 | 369 | $50.86 | $18.8K | 12,187 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-24 | 2026-02-25 | 750 | — | $0 | 12,556 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-24 | 2026-02-25 | 671 | — | $0 | 12,766 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-24 | 2026-02-25 | 1,125 | — | $0 | 12,409 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-24 | 2026-02-25 | 603 | $51.35 | $31.0K | 11,806 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-02-18 | 2026-02-20 | 13,500 | — | $0 | 13,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-02-18 | 2026-02-20 | 3,000 | — | $0 | 3,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-09-25 | 2025-09-26 | 1,875 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-09-25 | 2025-09-26 | 840 | $46.21 | $38.8K | 11,015 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-09-25 | 2025-09-26 | 1,875 | — | $0 | 11,855 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-09-10 | 2025-09-12 | 1,875 | — | $0 | 1,875 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-05 | 2025-03-05 | 577 | $33.05 | $19.1K | 9,635 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-05 | 2025-03-05 | 314 | $33.05 | $10.4K | 10,789 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-05 | 2025-03-05 | 577 | $33.05 | $19.1K | 10,212 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2025-02-23 | 2025-02-24 | 1,250 | — | $0 | 2,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2025-02-23 | 2025-02-24 | 1,250 | — | $0 | 11,103 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2025-02-22 | 2025-02-24 | 1,250 | — | $0 | 3,750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2025-02-22 | 2025-02-24 | 750 | — | $0 | 750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2025-02-22 | 2025-02-24 | 750 | — | $0 | 8,603 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2025-02-22 | 2025-02-24 | 1,250 | — | $0 | 9,853 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-02-21 | 2025-02-24 | 1,875 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-02-21 | 2025-02-24 | 927 | $39.15 | $36.3K | 7,853 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-02-21 | 2025-02-24 | 1,875 | — | $0 | 8,780 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-19 | 2025-02-21 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-19 | 2025-02-21 | 4,500 | — | $0 | 4,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-01-28 | 2025-01-29 | 1,875 | — | $0 | 1,875 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-12-27 | 2024-12-30 | 750 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-12-27 | 2024-12-30 | 1,875 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-12-27 | 2024-12-30 | 821 | $35.59 | $29.2K | 6,595 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-12-27 | 2024-12-30 | 1,875 | — | $0 | 7,416 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-12-27 | 2024-12-30 | 281 | $35.59 | $10.0K | 5,541 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-12-27 | 2024-12-30 | 750 | — | $0 | 5,822 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-12-23 | 2024-12-26 | 750 | — | $0 | 750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-12-23 | 2024-12-26 | 1,875 | — | $0 | 1,875 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2024-02-23 | 2024-02-27 | 1,250 | — | $0 | 3,750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2024-02-23 | 2024-02-27 | 1,250 | — | $0 | 5,208 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-02-23 | 2024-02-27 | 567 | $29.06 | $16.5K | 4,641 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-02-22 | 2024-02-26 | 25,000 | — | $0 | 25,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-02-22 | 2024-02-26 | 5,000 | — | $0 | 5,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2024-02-22 | 2024-02-26 | 750 | — | $0 | 1,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-02-22 | 2024-02-26 | 303 | $27.94 | $8.5K | 3,958 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2024-02-22 | 2024-02-26 | 750 | — | $0 | 4,261 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-12-22 | 2023-12-26 | 600 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2023-12-22 | 2023-12-26 | 204 | $27.66 | $5.6K | 3,243 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-12-22 | 2023-12-26 | 600 | — | $0 | 3,447 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-12-14 | 2023-12-18 | 600 | — | $0 | 600 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-23 | 2023-02-27 | 5,000 | — | $0 | 5,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-23 | 2023-02-27 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2023-02-22 | 2023-02-24 | 750 | — | $0 | 2,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2023-02-22 | 2023-02-24 | 750 | — | $0 | 2,497 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-02-16 | 2023-02-21 | 1,500 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-02-16 | 2023-02-21 | 1,500 | — | $0 | 1,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-01-12 | 2023-01-17 | 1,500 | — | $0 | 1,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-24 | 3,000 | — | $0 | 3,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-24 | 25,000 | — | $0 | 25,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-25 | 25,000 | — | $0 | 25,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-25 | 3,000 | — | $0 | 3,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2021-02-19 | 2021-02-23 | 25,000 | — | $0 | 25,000 | SEC↗ |